Exploratory treatment trials in multiple sclerosis using MRI: Sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups

Journal of Neurology Neurosurgery and Psychiatry

Volumn 64, Issue 1, 1998, Pages 50-55

  Tubridy, N ^a   Ader, H J ^b   Barkhof, F ^b   Thompson, A J ^a   Miller, D H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Multiple sclerosis; Power calculations; Treatment trials

Indexed keywords

GADOLINIUM;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 0031960472     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.64.1.50     Document Type: Article

References (29)

1. Noseworthy JH, Van der Voort MK, Wong CJ, et al. Interrater variability with the expanded disability status scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial. Neurology 1990;40:971-5.
2. Rudick RA, Antel J, Confavreux C, et al. Clinical outcomes assessment in multiple sclerosis. Ann Neurol 1996;40:469-79.
3. Whitaker JN, McFarland HF, Rudge P, et al. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1995;1:37-47.
4. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16.
5. Isaac C, Li DKB, Genton M, et al. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology 1988;38: 1511-5,
6. Willoughby EW, Grochowski E, Li DKB, et al. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 1989;25:43-9.
7. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
8. Thompson AJ, Miller DH, Youl B, et al. Serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis of varying disease duration. Neurology 1992;42:60-3.
9. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentate dimeglumine enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33:480-9.
10. Thorpe JW, Kidd D, Moseley IF, et al. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 1996;46: 373-8.
11. Kidd D, Thorpe JW, Kendall BE, et al. MR dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:15-9.
12. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-66.
13. Nauta JJP, Thompson AJ, Barkhof F, Miller DH. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel groups and cross-over designs. J Neurol Sci 1994;122:6-14.
14. Truyen L, Barkhof F, Tas M, et al. Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II treatment trials. Multiple Sclerosis 1997(in press).
15. van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomised, double-blind, placebo-controlled MR-monitored phase II trial. Neurology 1997 (in press).
16. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
17. Lublin F, Reingold SC. Defining the course of multiple sclerosis: results of an international survey. Neurology 1996; 46:907-11.
18. Efron B, Tibshirani R. Statistical analysis in the computer age. Science 1991;253:390-9.
19. Grossman RI, Gonzales-Scarano F, Atlas SW, et al. Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology 1986;169:117-22.
20. Losseff NA, Webb SL, O'Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive method with potential to monitor disease progression. Brain 1996;119:701-8.
21. Stone LA, Smith ME, Albert PS, et al. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender and age. Neurology 1995;45:1122-6.
22. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multi-centre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-8.
23. IFNB Multiple Sclerosis Study Group. Interferon β-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial. Neurology 1995;45:1277-85.
24. Kaurssis DM, Meiner Z, Lehmann D, et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 1996;47:341-6.
25. Miller DH, Thompson AJ, Morrisey SP, et al High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992;55:450-3.
26. Barkhof F, Tas MW, Frequin STFM, et al. Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. Neuroradiology 1994;36:382-7.
27. Kermode AG, Thompson AJ, Tofts PS, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 1990;113: 1477-89.
28. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by computerized data processing of 349 patients. Brain 1980;103:281-300.
29. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-34.